Boundless Bio, the precision oncology company working on treatments for oncogene-amplified cancers, is amping up its fundraising with a new $100 million series C round backed by Leaps by Bayer and RA Capital Management.
Bayer’s investment arm will join more than a dozen other investors, which include Arch Venture Partners, Vertex Ventures, Alexandria Venture Investments and many more, in supporting the fundraising.
Boundless launched in 2019 with a $49 million series A round, followed by a $105 million series B round in April 2021. Now, the company has a clinical candidate called BBI-355 working its way through a phase 1/2 study in patients with oncogene-amplified cancers. These cancers have managed to evade targeted therapies and immunotherapies, and Boundless has set out to change that, estimating that about 400,000 patients lack treatment options.
The new funds will go toward advancing BBI-355, supporting Boundless’ other preclinical candidates and the biotech’s clinical trial assay called ECHO.
BBI-355 is a checkpoint kinase 1 (CHK1) inhibitor being tested alone and in combination with other therapies in several cancer indications, including non-small cell lung cancer, breast cancer, head and neck squamous cell carcinoma and others, according to the POTENTIATE trial’s clinical record.
Boundless just announced that the first patient had been dosed last week.